Actelion Share Price

Stocks

31/17/31	Actelion : France's Sanofi raises earnings forecast, pleased with eczema drug uptake	RE
19/17/19	Johnson & Johnson : J&J sees sales growth in near-term; raises 2017 profit forecast	RE
19/17/19	Johnson & Johnson : J&J sees sales growth in near-term; raises 2017 profit forecast	RE
09/17/09	Actelion : Johnson & Johnson expects to complete Actelion purchase on June 16	RE
09/17/09	Actelion : Johnson & Johnson expects to complete Actelion purchase on June 16	RE
09/17/09	Actelion : Johnson & Johnson expects to complete of Actelion offer on June 16	RE
22/17/22	Akzo Nobel : Cross-border M&A between U.S. and European firms at 10 year high	RE
18/17/18	Actelion : Johnson & Johnson offers EU concessions over Actelion deal	RE
20/17/20	Actelion : Johnson & Johnson target Actelion could exit Swiss benchmark SMI index this month	RE
18/17/18	Actelion : Johnson & Johnson first quarter revenue misses estimates; new forecast includes Actelion	RE
05/17/05	Actelion : shareholders back R&D spinoff, keep J&J deal on track	RE
31/17/31	Actelion : J&J declares Actelion tender offer a success, sees closing in second quarter	RE
23/17/23	Genmab A/S : and J&J's cancer drug set for blockbuster sales this year	RE

06/20/06	Actelion : Pharmaceuticals US, Inc, - Results from Expert Delphi Consensus Survey on Treatment of Pulmonary Arterial Hypertension with Oral Prostacyclin Pathway Agents	AQ
31/17/31	Actelion : Cancellation of publicly held Actelion shares and delisting from SIX Swiss Exchange as of November 7, 2017	GL
30/17/30	Actelion : Befreiung von Publizitätspflichten zur Aufrechterhaltung der Kotierung	GL
16/17/16	Actelion : Johnson & Johnson Completes Acquisition of Actelion	GL
16/17/16	Actelion : Publication of Idorsia's prospectus relating to the listing of Idorsia Ltd on SIX Swiss Exchange	PU

29/18/29	Après Bioverativ, Sanofi s'empare de la biotech belge Ablynx pour 3,9 mrd EUR
29/18/29	Après Bioverativ, Sanofi rachète la biotech belge Ablynx pour 3,9 mrd EUR
22/18/22	Avec Bioverativ, Sanofi devient un leader mondial dans l'hémophilie
31/17/31	Actelion : Cancellation of publicly held Actelion shares and delisting from SIX Swiss Exchange as of November 7, 2017
30/17/30	Actelion: la décotation est agendée au 7 novembre

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ACTELION	-.--%	+0.99%	-	-	0
WUXI APPTEC CO., LTD.	+0.17%	+4.35%	+72.39%	+114.97%	7.35TCr
ARGENX SE	-0.09%	+14.22%	+55.49%	+90.57%	6.3TCr
INSMED INCORPORATED	+0.11%	-3.10%	+0.94%	+491.16%	2.81TCr
WUXI BIOLOGICS (CAYMAN) INC.	-1.40%	+4.81%	+60.85%	+20.35%	2.54TCr
BIONTECH SE	+1.26%	-0.05%	-17.59%	-15.96%	2.33TCr
GENMAB A/S	+0.52%	+4.32%	+40.22%	-14.83%	1.95TCr
PHARMAESSENTIA CORPORATION	-0.71%	-4.11%	+243.99%	+423.83%	1.82TCr
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-3.50%	-0.95%	+14.80%	+515.88%	1.65TCr
EXELIXIS, INC.	+1.53%	+3.49%	+40.68%	+151.75%	1.32TCr
Average	-0.21%	+3.63%	+56.86%	+197.53%	3.12TCr
Weighted average by Cap.	-0.13%	+5.69%	+56.93%	+164.01%